PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.
Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.
PMV Pharmaceuticals, Inc. reported full-year 2025 results and highlighted progress for its lead p53 reactivator, rezatapopt. The Phase 2 PYNNACLE trial showed a 34% overall response rate among 103 evaluable patients and a 46% response rate in 48 ovarian cancer patients, with responses lasting around 8 months.
Rezatapopt received U.S. FDA Orphan Drug Designation for TP53 Y220C–positive ovarian, fallopian tube, and primary peritoneal cancers, and Phase 1 data were published in the New England Journal of Medicine. As of December 31, 2025, PMV held $112.9 million in cash, cash equivalents, and marketable securities, providing expected cash runway to the end of the second quarter of 2027.
Net loss for 2025 was $77.7 million versus $58.7 million in 2024, driven mainly by higher research and development spending of $69.9 million. General and administrative expenses decreased to $16.3 million from $26.9 million, reflecting lower facility and personnel costs after prior-year restructuring.
PMV Pharmaceuticals is a precision oncology company developing small-molecule, tumor-agnostic therapies targeting mutant p53, led by rezatapopt for the p53 Y220C mutation. In the Phase 2 pivotal PYNNACLE trial, rezatapopt achieved a 34% overall response rate in 103 efficacy-evaluable patients and a 46% response rate in 48 ovarian cancer patients, with median response durations of 7.6 and 8.0 months. Rezatapopt has FDA Fast Track and orphan drug designations, and the company plans to submit a New Drug Application for platinum-resistant or refractory TP53 Y220C ovarian cancer in the first quarter of 2027. PMV is also advancing additional p53-focused programs, building companion diagnostics with FoundationOne CDx, and preparing commercialization infrastructure and IP protection around its platform.
PMV Pharmaceuticals’ large shareholder OrbiMed exits its position. OrbiMed Advisors LLC and OrbiMed Capital GP V LLC report that, as of March 2, 2026, they beneficially own 0 shares of PMV common stock, representing 0% of the 53,211,507 shares outstanding.
The exit follows sales by OrbiMed Private Investments V, LP of 505,000 shares on February 27, 2026 and 4,470,291 shares on March 2, 2026, each at a price of $1.62 per share. This amendment is characterized as an exit filing because their ownership fell by more than 1% and below the 5% reporting threshold.
ArrowMark Colorado Holdings, LLC filed an amended beneficial ownership report on PMV Pharmaceuticals, Inc. common stock. The firm reports beneficial ownership of 3,090,093 shares, representing 5.81% of the outstanding common stock as of the event date.
ArrowMark states it has sole voting and dispositive power over all reported shares and no shared power. The filing also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PMV Pharmaceuticals.
BML Investment Partners, L.P. filed an amended Schedule 13G reporting its ownership in PMV Pharmaceuticals, Inc.. The fund reports beneficial ownership of 5,292,000 shares of common stock, representing 9.9% of the class as of the event date.
BML has shared voting and dispositive power over all 5,292,000 shares and no sole voting or dispositive power. The filing notes that the securities are not held for the purpose of changing or influencing control of PMV Pharmaceuticals. Braden M. Leonard is deemed an indirect owner through BML Capital Management, LLC, the general partner.
PMV Pharmaceuticals (PMVP) filed its Q3 2025 10‑Q, reporting continued clinical investment and a wider loss as it advances rezatapopt. For the three months ended September 30, 2025, net loss was $21.1 million ($0.40 per share). Operating expenses were $22.5 million, driven by research and development of $18.2 million and general and administrative of $4.3 million. Interest income was $1.5 million.
For the nine months, net loss was $59.7 million, with $56.4 million used in operating cash flow. Cash, cash equivalents, and marketable securities totaled $129.3 million as of September 30, 2025. The company states it has adequate liquidity to operate for the next 12 months. Common shares outstanding were 52,993,238 at quarter‑end; 53,211,507 were outstanding as of November 12, 2025.
PMV reported interim Phase 2 data updates for the PYNNACLE trial of rezatapopt and plans to complete enrollment in the ovarian cohort by the first quarter of 2026, with an NDA submission targeted for the first quarter of 2027. The at‑the‑market program had $113.8 million of capacity remaining, with no sales during the quarter.
PMV Pharmaceuticals (PMVP) furnished an 8-K announcing financial results for the third quarter ended September 30, 2025. The company issued a press release on November 12, 2025, which is attached as Exhibit 99.1 and incorporated by reference.
The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act, limiting potential Section 18 liability and incorporation unless specifically referenced.
PMV Pharmaceuticals (PMVP) reported an insider transaction by its President and CEO (also a Director). On 10/27/2025, he exercised an employee stock option and acquired 220,643 shares of common stock at $1.37 per share.
Following the transaction, he beneficially owned 451,109 shares directly, plus indirect holdings of 165,307, 453,582, and 56,978 shares held by family trusts. The exercised option covered 220,643 shares and now has 0 remaining.
PMV Pharmaceuticals (PMVP) — Form 4 insider transaction: An affiliated holder reported a sale of 1,000,000 shares of Common Stock on 10/23/2025 at a price of $1.52 per share. Following the transaction, 4,975,291 shares were reported as beneficially owned indirectly.
According to the footnotes, the shares are held by OrbiMed Private Investments V, LP, with OrbiMed Capital GP V LLC as general partner and OrbiMed Advisors LLC as managing member. The filing notes that the reporting persons may be deemed to share voting and investment power through these relationships and include customary disclaimers of beneficial ownership beyond pecuniary interest. The reporting relationship is indicated as Director and 10% Owner.
Tang Capital group reports collective ownership of 4,720,357 shares of PMV Pharmaceuticals common stock, representing 8.9% of the outstanding class. The filing discloses that Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP and Tang Capital Partners International, LP share voting and dispositive power over these shares. The ownership figures are based on 52,990,864 shares outstanding as of August 6, 2025, per the issuer's quarterly report.
The statement clarifies that the reported securities were not acquired to change or influence control of PMV and lists office addresses and organizational domiciles for the reporting entities and individuals.
Tang Capital group reports collective ownership of 4,720,357 shares of PMV Pharmaceuticals common stock, representing 8.9% of the outstanding class. The filing discloses that Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP and Tang Capital Partners International, LP share voting and dispositive power over these shares. The ownership figures are based on 52,990,864 shares outstanding as of August 6, 2025, per the issuer's quarterly report.
The statement clarifies that the reported securities were not acquired to change or influence control of PMV and lists office addresses and organizational domiciles for the reporting entities and individuals.